Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations
In the EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58 studies, in patients with type 2 diabetes and established cardiovascular diseases or risk factors, a decrease in the risk of cardiovascular events and development or worsening of heart failure course without an increase in hypoglycemia incidence wa...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-02-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4807 |